UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 46

Sortiert nach

Childhood emotional abuse and neglect as predictors of psychological and physical symptoms in women presenting to a primary care practice

Child abuse & neglect, 2003-11, Vol.27 (11), p.1247-1258

2003

Link zum Volltext

Verfügbarkeit prüfen

Safety update on the use of recombinant activated factor VII in approved indications

Blood reviews, 2015-06, Vol.29, p.S34-S41

2015

Link zum Volltext

Verfügbarkeit prüfen

Glucagon-like peptide-1 receptor agonist use is associated with lower blood ferritin levels in people with type 2 diabetes and hemochromatosis: a nationwide register-based study

BMJ open diabetes research & care, 2023-06, Vol.11 (3), p.e003300

2023

Link zum Volltext

Verfügbarkeit prüfen

Risk Mitigation Strategy for Concizumab Clinical Trials after Pause Due to Non-Fatal Thrombotic Events

Blood, 2020-11, Vol.136 (Supplement 1), p.40-40

2020

Link zum Volltext

Verfügbarkeit prüfen

Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial

Thrombosis and haemostasis, 2007-10, Vol.98 (4), p.726

2007

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B

Transfusion (Philadelphia, Pa.), 2002-02, Vol.42 (2), p.190-197

2002

Link zum Volltext

Verfügbarkeit prüfen

Introduction

Haemophilia : the official journal of the World Federation of Hemophilia, 2012-07, Vol.18, p.1-2

SEREMETIS, STEPHANIE

2012

Link zum Volltext

Verfügbarkeit prüfen

11th Novo Nordisk Symposium on Haemostasis Management Vienna, Austria. 19-21 October 2011. Introduction

Haemophilia : the official journal of the World Federation of Hemophilia, 2012-07, Vol.18 Suppl 5, p.1-2

Seremetis, Stephanie

2012

Link zum Volltext

Verfügbarkeit prüfen

Introduction

Haemophilia : the official journal of the World Federation of Hemophilia, 2012-07, Vol.18 (s5), p.1-2

SEREMETIS, STEPHANIE

2012

Link zum Volltext

Verfügbarkeit prüfen

Introduction

Haemophilia : the official journal of the World Federation of Hemophilia, 2012-07, Vol.18 (s5), p.1-2

SEREMETIS, STEPHANIE

2012

Link zum Volltext

Verfügbarkeit prüfen

Mim8 Clinical Development Program: An Overview of the Frontier Studies

Blood, 2022-11, Vol.140 (Supplement 1), p.5630-5631

2022

Link zum Volltext

Verfügbarkeit prüfen

Beyond ABR: High FIX Activity Levels Translate into Clinical Benefits over Standard Prophylaxis

Blood, 2017-12, Vol.130, p.2372-2372

2017

Link zum Volltext

Verfügbarkeit prüfen

The use of recombinant activated factor VII in patients with acquired haemophilia

Blood reviews, 2015-06, Vol.29, p.S19-S25

2015

Link zum Volltext

Verfügbarkeit prüfen

Dose optimization of recombinant factor VIIa in the treatment of acute bleeding in haemophilia-associated inhibitors

Blood coagulation & fibrinolysis, 2003-06, Vol.14 Suppl 1 (SUPPLEMENT 1), p.S29-S30

Seremetis, Stephanie

2003

Link zum Volltext

Verfügbarkeit prüfen

Turoctocog alfa in the treatment of individuals with hemophilia A: review of quality of life data collected in Phase III trials

Clinical investigation, 2015-09, Vol.5 (9), p.755-766

2015

Link zum Volltext

Verfügbarkeit prüfen

Risk factors for inhibitor formation in haemophilia: a prevalent case-control study

Haemophilia : the official journal of the World Federation of Hemophilia, 2009-09, Vol.15 (5), p.1074-1082

2009

Link zum Volltext

Verfügbarkeit prüfen

Turoctocog alfa and drug development for hemophilia A

Expert opinion on orphan drugs, 2014-04, Vol.2 (4), p.419-431

2014

Link zum Volltext

Verfügbarkeit prüfen

Challenges of defining reliable clinical surrogate end points in haemophilia trials: a critical review

Blood coagulation & fibrinolysis, 2009-10, Vol.20 (7), p.488-493

2009

Link zum Volltext

Verfügbarkeit prüfen

Recombinant activated Factor VII in major surgery and trauma patients: a response: Wilson SJ, Bellamy MC, Giannoudis PV: The safety and efficacy of the administration of recombinant activated Factor VII in major surgery and trauma patients. Expert Opin. Drug Saf. (2005) 4(3):557-570

Expert opinion on drug safety, 2005-09, Vol.4 (5), p.813-814

2005

Link zum Volltext

Verfügbarkeit prüfen

Recombinant activated Factor VII in major surgery and trauma patients: a response

Expert opinion on drug safety, 2005-09, Vol.4 (5), p.813-814

2005

Link zum Volltext

Verfügbarkeit prüfen

Safety of Recombinant Activated Coagulation Factor VII in Non-Hemophilia Patients

Blood, 2004-11, Vol.104 (11), p.3978-3978

2004

Link zum Volltext

Verfügbarkeit prüfen

Effect of Recombinant Activated Factor VII (rFVIIa) on Platelet and Clotting Systems in Healthy Volunteers

Blood, 2005-11, Vol.106 (11), p.4053-4053

2005

Link zum Volltext

Verfügbarkeit prüfen

Variations in Ex-Vivo Assessments of Hemostasis

Blood, 2005-11, Vol.106 (11), p.4052-4052

2005

Link zum Volltext

Verfügbarkeit prüfen

An Open-Label, Randomized, Parallel, Multi-Center Trial Comparing the Safety and Efficacy of rFVIIa When Administered as I.V. Bolus or I.V. Continuous Infusion to Hemophilia Patients with Inhibitors during and after Surgery

Blood, 2004-11, Vol.104 (11), p.3975-3975

2004

Link zum Volltext

Verfügbarkeit prüfen

Hematology and women's health: issues in thrombosis and hemostasis

Seminars in hematology, 1999-07, Vol.36 (3)

SEREMETIS, Stephanie

1999

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 46

Suche als RSS-Feed

Aktive Filter

ThemaHemophilia

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(37)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(29)
Science & Technology
(23)
Life Sciences & Biomedicine
(22)
Biological And Medical Sciences
(18)
Hematology
(14)
Medical Sciences
(14)
Hematologic And Hematopoietic Diseases
(10)
Adult
(9)
Female
(8)
Middle Aged
(7)
Adolescent
(6)
Aged
(6)
Fundamental And Applied Biological Sciences. Psychology
(6)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(6)
Male
(6)
Haemophilia
(5)
Inhibitors
(5)
Leukemia, Myeloid, Acute - Genetics
(5)
Child
(4)
Hemophilia A - Drug Therapy
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Childhood emotional abuse and neglect as predictors of psychological and physical symptoms in women presenting to a primary care practice

Safety update on the use of recombinant activated factor VII in approved indications

Glucagon-like peptide-1 receptor agonist use is associated with lower blood ferritin levels in people with type 2 diabetes and hemochromatosis: a nationwide register-based study

Risk Mitigation Strategy for Concizumab Clinical Trials after Pause Due to Non-Fatal Thrombotic Events

Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial

Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B

Introduction

11th Novo Nordisk Symposium on Haemostasis Management Vienna, Austria. 19-21 October 2011. Introduction

Introduction

Introduction

Mim8 Clinical Development Program: An Overview of the Frontier Studies

Beyond ABR: High FIX Activity Levels Translate into Clinical Benefits over Standard Prophylaxis

The use of recombinant activated factor VII in patients with acquired haemophilia

Dose optimization of recombinant factor VIIa in the treatment of acute bleeding in haemophilia-associated inhibitors

Turoctocog alfa in the treatment of individuals with hemophilia A: review of quality of life data collected in Phase III trials

Risk factors for inhibitor formation in haemophilia: a prevalent case-control study

Turoctocog alfa and drug development for hemophilia A

Challenges of defining reliable clinical surrogate end points in haemophilia trials: a critical review

Recombinant activated Factor VII in major surgery and trauma patients: a response: Wilson SJ, Bellamy MC, Giannoudis PV: The safety and efficacy of the administration of recombinant activated Factor VII in major surgery and trauma patients. Expert Opin. Drug Saf. (2005) 4(3):557-570

Recombinant activated Factor VII in major surgery and trauma patients: a response

Safety of Recombinant Activated Coagulation Factor VII in Non-Hemophilia Patients

Effect of Recombinant Activated Factor VII (rFVIIa) on Platelet and Clotting Systems in Healthy Volunteers

Variations in Ex-Vivo Assessments of Hemostasis

An Open-Label, Randomized, Parallel, Multi-Center Trial Comparing the Safety and Efficacy of rFVIIa When Administered as I.V. Bolus or I.V. Continuous Infusion to Hemophilia Patients with Inhibitors during and after Surgery

Hematology and women's health: issues in thrombosis and hemostasis

Aktive Filter

Suchergebnisse filtern